-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Defining Essential Innovative Medicines and Measuring their Use in Europe
Sep 30, 2022
Access and affordability of medicines are top priority issues for healthcare stakeholders globally. Discussions in recent years have focused on the availability and use of recently launched medicines. Among those medicines are some that can be considered “essential” on the basis that at least one similar drug in a therapeutic group has been reviewed and received public reimbursement in at least half of the European countries assessed. To date, limited evidence has been presented to show per capita use across countries and for each of the clusters or groups of these Essential Innovative Medicines (EIMs).
This report has been prepared to provide evidence and context to discussions of medicine access and use in Europe. It draws upon research undertaken at the IQVIA Institute and other parts of IQVIA and taps IQVIA’s extensive global data assets that measure the use of medicines and their costs.
Use our interactive infographic to explore average per capital Essential Innovative Medicine use in Europe across therapy clusters and countries.
Key findings:
Exhibit 1 (Essential Innovative Medicines Methodology)
- From 2011–2020, 504 novel active substances (NASs) have become available to patients for the first time globally; however, these novel therapies are not always accessible to patients, with rising costs of many of these therapies leading to differences in reimbursement and affordability across countries and patient groups.
- Issues of disparities in medicine access and pricing are a continuing area of focus for the global community, with the World Health Organization (WHO) leading discussions around fair pricing through their Fair Pricing Forums, most recently held in 2021.
- While significant focus has been placed on understanding pricing, understanding and describing the use of medicines across countries is important for characterizing differences in access.
Exhibit 2 (Percent of 404 global NASs (2011–2020) reimbursed by country vs. percent of 94 innovative medicine groups with at least one NAS reimbursed)
- Of 504 NASs launched globally over the past decade, 404 have become available in Europe.
- There is significant variability in reimbursement status of NASs across countries, ranging from 58% of NASs being reimbursed in Germany to 4% in Portugal.
- Reimbursement status is higher across countries when evaluating at the group level (i.e., at least one drug reimbursed within the group), ranging from 71% of groups having at least one drug reimbursed in Germany to 12% in Portugal.
Exhibit 5 (Reimbursement status for 20 analyzed Essential Innovative Medicine groups)
- The seven clusters of EIM groups represent significant clinical advances in their disease areas and have all achieved public reimbursement for at least one drug in the group in more than half of the European countries analyzed.
- These countries independently assessed and arrived at reimbursement decisions, sometimes preferring one NAS over others in the EIM group, but consistently provide access to the technology in the group of innovative drugs to their populations.
- Austria consistently imposes restricted or conditional reimbursement status compared to other countries, and yet also has among the highest per capita use of these medicines.
Exhibit 11 (Average utilization of Essential Innovative Medicines across all groups, Europe average = 100)
- Each of the 20 EIM groups was measured in DDD per capita and compared to the European average DDD per capita indexed to 100 for the 35 European countries analyzed.
- The average utilization of these medicines across Europe is nearly half that in the U.S.
- Countries unweighted average indices show a range from a high of 236 in Luxembourg and 213 in Austria to a low of 10 in Ukraine and 16 in Bosnia.
Exhibit 20 (PD-1/PD-L1 inhibitors defined daily doses per 100k population, 2011–2021)
- The rate of adoption of EIMs varies across the European region by EIM group.
- For immuno-oncology checkpoint inhibitors of PD-1/PD-L1, the most common early adopter group of countries has volume per capita almost twice the European average in 2021 and reached the current European average volume one year ahead of the common early adopter group and three years ahead of the selective early group.
- Other countries who were not early adopters of EIMs remain at 42% of the European average volume use of PD-1/PD-L1 inhibitors as of 2021.